https://www.selleckchem.com/pr....oducts/n6-methyladen
Bis-choline-tetrathiomolybdate, introduced as WTX101 (now known as ALXN184, is a first-in-class copper-protein-binding agent for oral therapy of Wilson's disease. In contrast to other decoppering agents such as trientine or D-penicillamine it acts by forming a tripartite complex with copper and albumin, thereby detoxifying excess liver and blood copper through biliary excretion. Preclinical animal experimentation with this drug was typically done with the alternative ammonium salt of tetrathiomolybdate, which is expected to
Like
Comment
Share
